Current Opinion in Rheumatology · 6 Nov 2026
Update on biologics in SLE
Milena Delai, Vasileios C. Kyttarish-index 16
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Purpose of review Until recently, biologic treatment options for systemic lupus erythematosus (SLE) remained limited. Recent studies have substantially expanded the therapeutic landscape. We summarize where the field currently stands and which developments are likely to shape practice next. Recent findings Obinutuzumab, a type II anti-CD20 antibody, improved complete renal response in REGENCY, was approved for lupus nephritis in the United States and European Union, and was incorporated into the 2025 EULAR recommendations; in nonrenal SLE, ALLEGORY met its primary and all key secondary endpoints. A weekly subcutaneous formulation of the type I interferon receptor antagonist anifrolumab was approved after TULIP-SC. The dual BLyS/APRIL inhibitor telitacicept was effective in a Chinese phase 3 trial, and the CD40 ligand inhibitor dapirolizumab pegol met its primary endpoint in PHOENYCS GO. Ianalumab, litifilimab, and nipocalimab are advancing through phase 3 development. Summary SLE now has an expanding late-stage therapeutic pipeline. The principal challenges are now patient selection, sequencing and combination of agents, long-term safety and access.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Vasileios C. Kyttaris has the highest h-index among the authors (16).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (39)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 19 more references
A free account opens the rest of the citing papers and references on every paper’s page.